MSB 2.29% $1.28 mesoblast limited

“only news all year” he says … I guess that confirms you’re...

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 15,727 Posts.
    lightbulb Created with Sketch. 5757
    “only news all year” he says … I guess that confirms you’re still in denial about all the positive CHF news including the FDA Accelerated Approval pathway recommendation in March … lol




    UNITED STATES FOOD & DRUG ADMINISTRATION (FDA) SUPPORTS ACCELERATED APPROVAL PATHWAY FOR REXLEMESTROCEL-L IN END-STAGE HEART FAILURE PATIENTS WITH A LEFT VENTRICULAR ASSIST DEVICE (LVAD)


    Melbourne, Australia; March 11 and New York, USA; March 10, 2024: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that U.S. FDA supports an accelerated approval pathway for rexlemestrocel-L, Mesoblast’s allogeneic mesenchymal precursor cell (MPC) product, in patients with end-stage ischemic heart failure with reduced ejection fraction (HFrEF) and a left ventricular assist device (LVAD). FDA provided this feedback in formal minutes to the company following the Type B meeting held with FDA on February 21, 2024 for rexlemestrocel-L (Revascor® under the existing Regenerative Medicine Advanced Therapy (RMAT) designation.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
$1.28
Change
-0.030(2.29%)
Mkt cap ! $1.461B
Open High Low Value Volume
$1.32 $1.35 $1.28 $1.677M 1.289M

Buyers (Bids)

No. Vol. Price($)
10 44452 $1.28
 

Sellers (Offers)

Price($) Vol. No.
$1.29 23596 1
View Market Depth
Last trade - 16.10pm 04/11/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.